Bernard D. Beitman M.D., Niels C. Beck, William E. Deuser, Cameron S. Carter, Jonathan R., T. Davidson, Richard J. Maddock
{"title":"Patient stage of change predicts outcome in a panic disorder medication trial","authors":"Bernard D. Beitman M.D., Niels C. Beck, William E. Deuser, Cameron S. Carter, Jonathan R., T. Davidson, Richard J. Maddock","doi":"10.1002/anxi.3070010205","DOIUrl":null,"url":null,"abstract":"<p><i>Objective</i>: The authors test the hypothesis that patient readiness to change predicts outcome in a placebo-controlled medication trial. <i>Method</i>: Outpatients with panic disorder and agoraphobia completed the Stages of Change (SOC) questionnaire, a measure of readiness to change, before being randomly assigned either sustained release (SR) adinazolam or placebo in a 4-week double-blind trial. <i>Results</i>: In the “intent to treat” analysis, for the 202 subjects who made at least one visit after baseline, adinazolam SR was significantly more effective than placebo on most major outcome measures. Of the 126 subjects who completed the SOC questionnaire, regression analyses showed significant correlations between SOC scores and all 5 outcome measures. In a second analysis, cluster membership based on SOC scores was predictive of outcome on 3 of 5 measures. In each statistical analysis, subjects who were not predisposed to change as measured by the SOC were significantly less likely to change. <i>Conclusions</i>: Patient readiness to change was strongly correlated with outcome in a placebo-controlled panic disorder trial with an effective medication. In this study, the SOC category, Precontemplation (i.e., those subjects who reported the belief that they had no problem) were less likely to change compared to those who believed that they had a problem. <i>Anxiety</i> 1:64–69 (1994). © 1994 Wiley-Liss, Inc.</p>","PeriodicalId":79474,"journal":{"name":"Anxiety","volume":"1 2","pages":"64-69"},"PeriodicalIF":0.0000,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/anxi.3070010205","citationCount":"68","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anxiety","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anxi.3070010205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 68
Abstract
Objective: The authors test the hypothesis that patient readiness to change predicts outcome in a placebo-controlled medication trial. Method: Outpatients with panic disorder and agoraphobia completed the Stages of Change (SOC) questionnaire, a measure of readiness to change, before being randomly assigned either sustained release (SR) adinazolam or placebo in a 4-week double-blind trial. Results: In the “intent to treat” analysis, for the 202 subjects who made at least one visit after baseline, adinazolam SR was significantly more effective than placebo on most major outcome measures. Of the 126 subjects who completed the SOC questionnaire, regression analyses showed significant correlations between SOC scores and all 5 outcome measures. In a second analysis, cluster membership based on SOC scores was predictive of outcome on 3 of 5 measures. In each statistical analysis, subjects who were not predisposed to change as measured by the SOC were significantly less likely to change. Conclusions: Patient readiness to change was strongly correlated with outcome in a placebo-controlled panic disorder trial with an effective medication. In this study, the SOC category, Precontemplation (i.e., those subjects who reported the belief that they had no problem) were less likely to change compared to those who believed that they had a problem. Anxiety 1:64–69 (1994). © 1994 Wiley-Liss, Inc.
病人的变化阶段预测结果在恐慌症药物试验
目的:在安慰剂对照药物试验中,作者检验了患者改变的准备程度预测结果的假设。方法:在为期4周的双盲试验中,惊恐障碍和广场恐怖症门诊患者完成了变化阶段(SOC)问卷,这是一种衡量改变准备程度的量表,然后随机分配缓释(SR) adinazolam或安慰剂。结果:在“治疗意向”分析中,对于202名在基线后至少就诊一次的受试者,adinazolam SR在大多数主要结果测量上明显比安慰剂更有效。在126名完成了SOC问卷的被试中,回归分析显示SOC得分与所有5项结果指标之间存在显著的相关性。在第二次分析中,基于SOC分数的集群隶属度预测了5项措施中的3项结果。在每一项统计分析中,那些不倾向于改变的被试都显著地降低了改变的可能性。结论:在使用有效药物的安慰剂对照惊恐障碍试验中,患者改变的准备程度与结果密切相关。在这项研究中,SOC类别,pre默想(即那些认为自己没有问题的受试者)与那些认为自己有问题的受试者相比,不太可能改变。焦虑:64 - 69(1994)。©1994 Wiley-Liss, Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。